Work

Techniques

Year: 2010
Type: article
Abstract: Results: We used NSCLC cell lines to verify that the mutation-specific antibodies can specifically detect EGFR mutations and the EpCAM antibody was selectively labeled at the epithelial cells by fluorescence immunocytochemistry.Next, we tested the cancer cell lines enriched from mixed with blood.Finally, we confirmed the assay from the cells recovered from the blood or pleural effusion of late stage NSCLC patients.Conclusions: Fluorescence immunocytochemistry with mutation-specific antibodies to detect EGFR mutations on the tumor cells from blood or pleural effusion is a reliable, easily accessible and cost efficient assay for patient selective to target therapy, especially in the late stage NSCLC patients without tumor tissue or the patients treated by TKI for following up the response. 1916
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,480
OpenAlex ID: W4232125706
FWCI:
Cites:
Cited by:
Related to: 9